No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits Christian Olsson, MD, Agneta Siegbahn, MD, PhD,

Slides:

Advertisements

Similar presentations

The effect of cardiotomy suction on the brain injury marker S100β after cardiopulmonary bypass Russell E Anderson, MD, PhD, Lars-Olof Hansson, MD, PhD,

Advertisements

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits Piet G.M. Jansen, MD,

Heparin-coated cardiopulmonary bypass equipment. II

Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration Jean-Olivier Defraigne, MD, PhD,

Effect of complement inhibition and heparin coating on artificial surface–induced leukocyte and platelet activation Knut Tore Lappegård, MD, Michael.

Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface- Induced Eicosanoid Production Knut Tore Lappegård, MD, Johan Riesenfeld,

Sally Bannan, Amanda Danby, Dahlia Cowan, Saeed Ashraf, Paul G Martin

Cerebral Oxygen Saturation Does Not Normalize Until After Stage 2 Single Ventricle Palliation Kathleen N. Fenton, MD, Katherine Lessman, BS, Kimberly.

Attenuation of Changes in Leukocyte Surface Markers and Complement Activation With Heparin-Coated Cardiopulmonary Bypass Oddvar Moen, MD, Kolbjørn Høgåsen,

A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients Lena Lindholm,

Rewarming Rate During Cardiopulmonary Bypass Is Associated With Release of Glial Fibrillary Acidic Protein Daijiro Hori, MD, Allen D. Everett, MD, Jennifer.

Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study Song Wan, MD, PhD, Jean-Louis.

Randomized Comparison Between Normothermic and Hypothermic Cardiopulmonary Bypass in Pediatric Open-Heart Surgery Massimo Caputo, MD, Simon Bays, Chris.

P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J

James L Zellner, MD, Scott B Kribbs, BS, B

Bashir M Matata, PhD, Andrzej W Sosnowski, MD, Manuel Galiñanes

Assessment of heparin anticoagulation: comparison of two commercially available methods Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor,

Is kidney function altered by the duration of cardiopulmonary bypass?

Leukocyte depletion during cardiac operation: a new approach through the venous bypass circuit Y.John Gu, MD, PhD, A.J de Vries, MD, Paulien Vos, Piet.

Total Liquid Ventilation Reduces Lung Injury in Piglets After Cardiopulmonary Bypass Lijun Jiang, MD, Qiang Wang, MD, Yinglong Liu, MD, Ming Du, MD, Xiangdong.

Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization Hiroshi Kumano, MD, PhD, Shigefumi Suehiro, MD, PhD, Koji.

Simvastatin Increases Neutrophil Apoptosis and Reduces Inflammatory Reaction After Coronary Surgery Massimo Chello, MD, Amedeo Anselmi, MD, Cristiano.

Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only Thierry P Carrel, MD, Mike Schwanda, MD,

Susanne Lison, MD, Michael Spannagl, MD, PhD, Wulf Dietrich, MD, PhD

Hedi H Schreurs, Marianne J Wijers, Y

Effect of Heparin Loading During Congenital Heart Operation on Thrombin Generation and Blood Loss Sophronia O Turner-Gomes, MB, ChB, Evan P Nitschmann,

Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass Martin Strüber, MD, Jochen T Cremer, MD, Bernhard.

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery John L Francis, PhD, George J Palmer, MD, Rebecca Moroose,

Relationship Between Antiinflammatory Cytokine Interleukin-10 and Lactate Concentrations in Neonates Undergoing the Arterial Switch Operation Kyrylo.

Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass Alvise Bernabei,

Comparative effects of propofol versus fentanyl on cerebral oxygenation state during normothermic cardiopulmonary bypass and postoperative cognitive dysfunction

Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Alan F Merry, FANZCA, Peter J Raudkivi, FRACS, Neil G Middleton, FCASA,

Clinical performance and biocompatibility of poly(2-methoxyethylacrylate)—coated extracorporeal circuits Serdar Gunaydin, MD, Bora Farsak, MD, Mustafa.

John S. Ikonomidis, MD, PhD, Ebony J

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Abdellah Aouifi, MD, Pascale Blanc, MD, Vincent.

Anne H Kuitunen, MD, Lasse J Heikkilä, MD, Markku T Salmenperä, MD

Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model Hitoshi Suhara, MD, Yoshiki Sawa, MD, Motonobu Nishimura,

Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated.

Complement and granulocyte activation in two different types of heparinized extracorporeal circuits Eivind Øvrum, MDa, Tom Eirik Mollnes, MD, PhDb, Erik.

Benjamin C. Sun, MD, Timothy A. Dickinson, CCP, Eric A

Infant cardiopulmonary bypass: a procoagulant state

Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Julio C Vasquez, MD, Anna Vichiendilokkul, PharmD, Syed Mahmood, MD,

Individualized heparin and protamine management in infants and children undergoing cardiac operations Massimiliano Codispoti, MD, Christopher A Ludlam,

Mudassir I Dar, Timothy Gillott, Franco Ciulli, MD, Graham J Cooper

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary.

Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass Nobuhiko Hayashida, MD, PhD, Hiroshi Tomoeda, MD, Takeshi Oda, MD,

Ronald A. Bronicki, MD, Carl L. Backer, MD, Harris P

Inflammatory Mediators in Adults Undergoing Cardiopulmonary Bypass: Comparison of Centrifugal and Roller Pumps Saeed Ashraf, John Butler, Yi Tian, Dahlia.

Sune Damgaard, MD, PhD, Claus H. Nielsen, MD, PhD, Lars W

Time course of proinflammatory and anti-inflammatory responses after cardiac operation: monocyte HLA-DR expression Y.John Gu, MD, PhD, Willem van Oeveren,

Effect of cardiopulmonary bypass on pulmonary gas exchange: a prospective randomized study Craig M Cox, Raimondo Ascione, MD, Alan M Cohen, Ian M Davies,

Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair Greg Stratmann, MD, PhD, Isobel A Russell,

Aprotinin Enhances the Endogenous Release of Interleukin-10 After Cardiac Operations Gary E Hill, Robert P Diego, Alfred H Stammers, Suzanne M Huffman,

Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost Michael J Ray, PhD, Mark F O’Brien

Effect of Nitric Oxide Gas on Platelets During Open Heart Operations

Generation of platelet-derived microparticles in patients undergoing cardiac surgery is not affected by complement activation Jeanette M van den Goor,

Fraser D. Rubens, MD, MS, Gilbert Lavalee, Marc A

Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit Michael J Ray, PhD, Majella M Hales,

Grethe Bergseth, BS, John D

Comparison of Blood Activation in the Wound, Active Vent, and Cardiopulmonary Bypass Circuit Olivier Fabre, MD, PhD, André Vincentelli, MD, PhD, Delphine.

Advances in the heart-lung machine after John and Mary Gibbon

Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient

Effects of Methylprednisolone and a Biocompatible Copolymer Circuit on Blood Activation During Cardiopulmonary Bypass Fraser D. Rubens, MD, Howard Nathan,

Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury Christine S Rinder, MD, Manuel Fontes, MD,

Karl A. Bocchieri, BS, CCP, S. Jacob Scheinerman, MD, L

Safety of low hematocrits during cardiopulmonary bypass

A randomized trial of antithrombin concentrate for treatment of heparin resistance Mathew R Williams, MD, Alyssa B D’Ambra, BA, James R Beck, Talia B.

Thrombophilic Variables Do Not Increase the Generation or Procoagulant Activity of Thrombin During Cardiopulmonary Bypass Peter Raivio, MD, Jari Petäjä,

High-Dose ϵ-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations Balthasar Eberle, Eckhard Mayer, Gerhard.

Presentation transcript:

No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits Christian Olsson, MD, Agneta Siegbahn, MD, PhD, Eric Haldén, MD, PhD, Bo Nilsson, MD, PhD, Per Venge, MD, PhD, Stefan Thelin, MD, PhD The Annals of Thoracic Surgery Volume 69, Issue 3, Pages 743-749 (March 2000) DOI: 10.1016/S0003-4975(99)01502-7

Fig 1 Median plasma levels of lactoferrin (LF) during and after cardiopulmonary bypass with heparin-coated circuits and reduced (group R, filled triangles ▴) or standard (group S, open squares □) doses of systemic heparin. Error bars represent interquartile ranges. (Baseline = at anesthesia; CPB = on cardiopulmonary bypass, Prot = after protamine.) The Annals of Thoracic Surgery 2000 69, 743-749DOI: (10.1016/S0003-4975(99)01502-7)

Fig 2 Median plasma levels of myeloperoxidase (MPO) during and after cardiopulmonary bypass with heparin-coated circuits and reduced (group R, filled triangles ▴) or standard (group S, open squares □) doses of systemic heparin. Error bars represent interquartile ranges. (Baseline = at anesthesia; CPB = on cardiopulmonary bypass; Prot = After protamine.) The Annals of Thoracic Surgery 2000 69, 743-749DOI: (10.1016/S0003-4975(99)01502-7)

Fig 3 Median plasma levels of Interleukin-6 (IL-6) during and after cardiopulmonary bypass with heparin-coated circuits and reduced (group R, filled triangles ▴) or standard (group S, open squares □) doses of systemic heparin. Error bars represent interquartile ranges. (Baseline = at anesthesia; CPB = on cardiopulmonary bypass; Prot = after protamine.) The Annals of Thoracic Surgery 2000 69, 743-749DOI: (10.1016/S0003-4975(99)01502-7)

Fig 4 Median plasma levels of terminal [C5a-9] complement complex (TCC) during and after cardiopulmonary bypass with heparin-coated circuits and reduced (group R, filled triangles ▴) or standard (group S, open squares □) doses of systemic heparin. Error bars represent interquartile ranges. (Baseline = at anesthesia; CPB = on cardiopulmonary bypass; Prot = after protamine.) The Annals of Thoracic Surgery 2000 69, 743-749DOI: (10.1016/S0003-4975(99)01502-7)

Fig 5 Median plasma levels of complement factor C3a during and after cardiopulmonary bypass with heparin-coated circuits and reduced (group R, filled triangles ▴) or standard (group S, open squares □) doses of systemic heparin. Error bars represent interquartile ranges. (Baseline = at anesthesia; CPB = on cardiopulmonary bypass; Prot = after protamine.) The Annals of Thoracic Surgery 2000 69, 743-749DOI: (10.1016/S0003-4975(99)01502-7)

Fig 6 Median plasma levels of thrombin-antithrombin complex (TAT) during and after cardiopulmonary bypass with heparin-coated circuits and reduced (group R, filled triangles ▴) or standard (group S, open squares □) dose of systemic heparin. Error bars represent interquartile ranges. (Baseline = at anesthesia; CPB = on cardiopulmonary bypass; Prot = after protamine.) The Annals of Thoracic Surgery 2000 69, 743-749DOI: (10.1016/S0003-4975(99)01502-7)